Compare Sana Biotechnology Inc (SANA) vs STMicroelectronics NV (STM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs STMicroelectronics NV — how do they compare? Sana Biotechnology Inc trades at $3.17 (market cap $1.03B), while STMicroelectronics NV trades at $51.61 (market cap $46.67B). The key difference: STMicroelectronics NV is far larger — about 45.3× Sana Biotechnology Inc's market cap, and STMicroelectronics NV pays a 0.69% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| SANA | STM | |
|---|---|---|
Market Cap | $1.03B | $46.67B |
Sector | Health | Financials |
52-Week High | $5.92 | $79.91 |
52-Week Low | $2.68 | $21.20 |
Enterprise Value | $946.04M | $44.19B |
Dividend Yield | — | 0.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
STM trades at $51.97, down 0.52% today, with a bullish technical signal and support near $52. The company reported mixed Q2 2026 earnings, beating EPS estimates but showing a net income margin of -0.39% in 2026. Recent news highlights AI data-center revenue targets exceeding $2 billion by 2027, driven by optical connectivity and industrial automation, though near-term margins face pressure from fab transitions.
Outlook is cautiously optimistic with a consensus price target of $71.83, implying 38% upside, supported by AI growth catalysts. Risks include earnings volatility, competitive pressures in semiconductors, and macroeconomic headwinds. Analysts are 52% buy-rated, but investors should monitor execution on profitability improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About STMicroelectronics NV
A merger between Italian firm SGS Microelettronica and the nonmilitary business of Thomson Semiconductors in France formed STMicroelectronics in 1987. STMicro is a leader in a variety of semiconductor products, including analog chips, discrete power semiconductors, microcontrollers, and sensors. STMicro is an especially prominent chip supplier into the industrial and automotive industries.
Read more on STM →
